林业发展局批准Alhemo防治A型或B型抑制剂患者血友病出血。 The FDA approves Alhemo for preventing bleeding in hemophilia A or B patients with inhibitors.

林业发展局已核准Alhemo(Concizumab-mtci)预防或减少12岁及以上患有A型或B型血友病抑制剂的成人和儿科病人的出血情况。 The FDA has approved Alhemo (concizumab-mtci) for preventing or reducing bleeding episodes in adult and pediatric patients aged 12 and older with hemophilia A or B with inhibitors. 这种注射治疗基于显示年出血率下降86%的试验数据,为病人提供了一种新的选择,即通过预先填充的注射笔进行亚切注射。 This injectable treatment, based on trial data showing an 86% reduction in annual bleeding rate, offers a new option for patients, administered via a prefilled pen for subcutaneous injection. 常见副作用包括注射场反应和蜂窝。 Common side effects include injection site reactions and hives.